XML 10 R2.htm IDEA: XBRL DOCUMENT v3.22.2
Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
ASSETS    
Cash and cash equivalents $ 33,348 $ 24,647
Marketable securities 39,643 70,323
Prepaid and other current assets 1,956 1,212
Total current assets 74,947 96,182
Property and equipment, net 282 62
Other Investments 10,000 0
Other assets 648 764
Total assets 85,877 97,008
Liabilities    
Accounts payable 1,097 1,934
Accrued liabilities 2,260 2,589
Total current liabilities 3,357 4,523
Other long-term liabilities 383 485
Total liabilities 3,740 5,008
Commitments and Contingencies
Stockholders' Equity    
Preferred stock, authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 0.001 share of common stock, $0.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at June 30, 2022 and December 31, 2021, respectively 0 0
Common stock, $0.001 par value, authorized 500,000,000 shares; issued 60,594,329 and 59,800,792 shares at June 30, 2022 and December 31, 2021, respectively; and outstanding, 60,583,249 and 59,789,712 shares at June 30, 2022 and December 31, 2021, respectively 61 60
Additional paid-in capital 546,976 545,988
Treasury stock, at cost; 11,080 shares at June 30, 2022 and December 31, 2021 (708) (708)
Accumulated deficit (463,868) (453,016)
Accumulated other comprehensive loss (70) (70)
Total Caladrius Biosciences, Inc. stockholders' equity 82,391 92,254
Non-controlling interests (254) (254)
Total stockholders' equity 82,137 92,000
Total liabilities, non-controlling interests and stockholders' equity $ 85,877 $ 97,008